Trial Profile
Comparison of strut coverage between previous generation durable polymer everolimus-eluting stent (XIENCE ) and new generation bioabsorbable polymer everolimus-eluting stent (SYNERGY) in patients with acute coronary syndrome at 2 weeks and 4 months after stent implantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Acute coronary syndromes; Myocardial infarction
- Focus Therapeutic Use
- 30 Sep 2017 New trial record
- 30 Aug 2017 Results (N= 45 , 25 patients with Xience and 22 patients with Synergy for serial optical coherence tomography analysis) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology